AstraZeneca: We don't shy away from patent fights
This article was originally published in Scrip
Executive Summary
When it comes to defending its intellectual property, AstraZeneca doesn't shy away from using the American court system against firms trying to "capture and infringe on our patents," said Dr Scott Alban, vice president of global intellectual property and innovative medicines and MedImmumne R&D.